Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139750
Status:
COMPLETED
Last Update Posted:
2007-06-04
First Post:
2005-08-29
Brief Title:
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526555 and Placebo for Smoking Cessation
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Randomized Multicenter Study Evaluating The Efficacy And Safety Of CP-526555 In Smokers Motivated To Stop Smoking
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526555 for 12 weeks compared with placebo for smoking cessation including post-treatment follow-up of smoking status to one year from randomization A small satellite protocol A3051048 investigated safety of a second course of therapy in subjects who did not quit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None